{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:12:53Z","timestamp":1772910773441,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant melanoma in dogs is considered to be largely resistant to conventional chemotherapy, although responses to carboplatin have been documented. Invasion and early metastasis are common features of certain melanoma subtypes that contribute to tumour progression despite aggressive local and systemic therapy. Upregulation of the PI3K\/AKT\/mTOR pathway has been observed in canine malignant melanoma and may represent a potential target for therapy. Rapamycin (sirolimus) and everolimus are commercially available small molecule inhibitors that target mTOR and therefore may have anticancer activity in canine melanoma. It was hypothesized that there is synergism between rapamycin or everolimus and platinum chemotherapy, and that combination drug treatment would inhibit target\/downstream proteins involved in cell viability\/proliferation and increase cell death in canine melanoma cells. It was further hypothesized that rapamycin or everolimus would impact metabolism by reducing glycolysis in these cells. Four canine melanoma cell lines were treated in vitro with rapamycin and everolimus as sole treatment or combined with carboplatin. Cell viability, apoptosis, target modulation, and glycolytic metabolism were evaluated by crystal violet colourimetric assay, Annexin V\/PI flow cytometry, western blotting, and Seahorse bioanalyzer, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When combined with carboplatin chemotherapy, rapamycin or everolimus treatment was overall synergistic in reducing cell viability. Carboplatin-induced apoptosis was noted at 72\u2009h after treatment compared to the vehicle control. Levels of phosphorylated mTOR were reduced by rapamycin and everolimus in all four cell lines, but activation of the downstream protein p70S6K was not consistently reduced by treatment in two of the cell lines. Both mTOR inhibitors decreased the extracellular acidification rate of canine melanoma cells, indicating reduced cancer cell glycolytic activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Inhibition of mTOR by rapalogs, such as rapamycin and everolimus combined with carboplatin chemotherapy may have activity in canine melanoma. Future mechanistic investigation is warranted, including in vivo assessment of this combination therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-03089-0","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T08:02:31Z","timestamp":1639209751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells"],"prefix":"10.1186","volume":"17","author":[{"given":"Sarah","family":"Bernard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3617-4582","authenticated-orcid":false,"given":"Andrew C.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton M.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7149","authenticated-orcid":false,"given":"Anthony J.","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"issue":"6","key":"3089_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1354\/vp.39-6-651","volume":"39","author":"SH Smith","year":"2002","unstructured":"Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002;39(6):651\u201378.","journal-title":"Vet Pathol"},{"issue":"1","key":"3089_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1476-5829.2012.00338.x","volume":"12","author":"G Dank","year":"2014","unstructured":"Dank G, Rassnick KM, Sokolovsky Y, Garrett LD, Post GS, Kitchell BE, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision: adjuvant carboplatin for oral malignant melanoma. Vet Comp Oncol. 2014;12(1):78\u201384.","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"3089_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1740-8261.2003.tb00468.x","volume":"44","author":"DR Proulx","year":"2003","unstructured":"Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound. 2003;44(3):352\u20139.","journal-title":"Vet Radiol Ultrasound"},{"issue":"1","key":"3089_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1939-1676.2010.0627.x","volume":"25","author":"CA Manley","year":"2011","unstructured":"Manley CA, Leibman NF, Wolchok JD, Rivi\u00e8re IC, Bartido S, Craft DM, et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs: malignant melanoma vaccination. J Vet Intern Med. 2011;25(1):94\u20139.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"3089_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1939-1676.1994.tb03231.x","volume":"8","author":"KE Bateman","year":"1994","unstructured":"Bateman KE, Catton PA, Pennock PW, Kruth SA. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med. 1994;8(4):267\u201372.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3089_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/00480169.2012.699433","volume":"61","author":"L Brockley","year":"2013","unstructured":"Brockley L, Cooper M, Bennett P. Malignant melanoma in 63 dogs (2001\u20132011): the effect of carboplatin chemotherapy on survival. N Z Vet J. 2013;61(1):25\u201331.","journal-title":"N Z Vet J"},{"issue":"1","key":"3089_CR7","first-page":"96","volume":"17","author":"KP Freeman","year":"2003","unstructured":"Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987\u20131997). J Vet Intern Med. 2003;17(1):96\u2013101.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"3089_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2460\/javma.245.4.401","volume":"245","author":"SE Boston","year":"2014","unstructured":"Boston SE, Lu X, Culp WTN, Montinaro V, Romanelli G, Dudley RM, et al. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001\u20132012). J Am Vet Med Assoc. 2014;245(4):401\u20137.","journal-title":"J Am Vet Med Assoc"},{"issue":"9","key":"3089_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","volume":"218","author":"KM Rassnick","year":"2001","unstructured":"Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc. 2001;218(9):1444\u20138.","journal-title":"J Am Vet Med Assoc"},{"issue":"8","key":"3089_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/cells8080803","volume":"8","author":"J Chamcheu","year":"2019","unstructured":"Chamcheu J, Roy T, Uddin M, Banang-Mbeumi S, Chamcheu R-C, Walker A, et al. Role and therapeutic targeting of the PI3K\/Akt\/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8(8):803.","journal-title":"Cells."},{"issue":"6","key":"3089_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/pcmr.12512","volume":"29","author":"B-R Wei","year":"2016","unstructured":"Wei B-R, Michael HT, Halsey CHC, Peer CJ, Adhikari A, Dwyer JE, et al. Synergistic targeted inhibition of MEK and dual PI3K\/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment Cell Melanoma Res. 2016;29(6):643\u201355.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"3089_CR12","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H P\u00f3pulo","year":"2012","unstructured":"P\u00f3pulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886\u2013918.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3089_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1354\/vp.39-4-458","volume":"39","author":"A Koenig","year":"2002","unstructured":"Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. Expression and significance of p53, Rb, p21\/waf-1, p16\/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002;39(4):458\u201372.","journal-title":"Vet Pathol"},{"issue":"1","key":"3089_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Targ Oncol. 2011;6(1):17\u201327.","journal-title":"Targ Oncol"},{"issue":"2","key":"3089_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2460\/ajvr.70.2.263","volume":"70","author":"MS Kent","year":"2009","unstructured":"Kent MS, Collins CJ, Ye F. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. Am J Vet Res. 2009;70(2):263\u20139.","journal-title":"Am J Vet Res"},{"issue":"5","key":"3089_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell."},{"issue":"3191","key":"3089_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309.","journal-title":"Science."},{"issue":"4","key":"3089_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11033-015-3858-x","volume":"42","author":"R Courtnay","year":"2015","unstructured":"Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42(4):841\u201351.","journal-title":"Mol Biol Rep"},{"key":"3089_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1\u2423 expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:11.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"3089_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011013","volume":"5","author":"MC Paoloni","year":"2010","unstructured":"Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One. 2010;5(6):e11013.","journal-title":"PLoS One"},{"issue":"3","key":"3089_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/vco.12044","volume":"13","author":"JS Fowles","year":"2015","unstructured":"Fowles JS, Denton CL, Gustafson DL. Comparative analysis of MAPK and PI3K\/AKT pathway activation and inhibition in human and canine melanoma. Vet Comp Oncol. 2015;13(3):288\u2013304.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"3089_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"3089_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1634\/theoncologist.2018-0100","volume":"23","author":"J Vera Aguilera","year":"2018","unstructured":"Vera Aguilera J, Rao RD, Allred JB, Suman VJ, Windschitl HE, Kaur JS, et al. Phase II study of everolimus in metastatic malignant melanoma (NCCTG-N0377, Alliance). Oncologist. 2018;23(8):887.","journal-title":"Oncologist."},{"issue":"4","key":"3089_CR24","first-page":"731","volume":"35","author":"N Gulati","year":"2009","unstructured":"Gulati N, Kersy M, Albert L, Murali R, Jhanwar-Uniyal M. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol. 2009;35(4):731\u201340.","journal-title":"Int J Oncol"},{"issue":"4","key":"3089_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ng1755","volume":"38","author":"P Yeh","year":"2006","unstructured":"Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat Genet. 2006;38(4):489\u201394.","journal-title":"Nat Genet"},{"issue":"6","key":"3089_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3089_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41419-018-1280-8","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang Y, Chen D, Liu H, Yang K. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT\/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10(2):41.","journal-title":"Cell Death Dis"},{"issue":"8","key":"3089_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.bbabio.2017.01.013","volume":"1858","author":"M Hosseini","year":"2017","unstructured":"Hosseini M, Kasraian Z, Rezvani HR. Energy metabolism in skin cancers: a therapeutic perspective. Biochim Biophys Acta Bioenerg. 2017;1858(8):712\u201322.","journal-title":"Biochim Biophys Acta Bioenerg"},{"issue":"1","key":"3089_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2012.02.030","volume":"149","author":"I Garcia-Cao","year":"2012","unstructured":"Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VCJ, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012;149(1):49\u201362.","journal-title":"Cell."},{"issue":"3\u20134","key":"3089_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.vetimm.2006.11.009","volume":"115","author":"L Rebuzzi","year":"2007","unstructured":"Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol. 2007;115(3\u20134):320\u201333.","journal-title":"Vet Immunol Immunopathol"},{"issue":"8","key":"3089_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2460\/ajvr.69.8.1079","volume":"69","author":"IK Gordon","year":"2008","unstructured":"Gordon IK, Ye F, Kent MS. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res. 2008;69(8):1079\u201384.","journal-title":"Am J Vet Res"},{"issue":"3","key":"3089_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194224","volume":"13","author":"A Parrales","year":"2018","unstructured":"Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, et al. Comparative oncology approach to drug repurposing in osteosarcoma. PLoS One. 2018;13(3):e0194224.","journal-title":"PLoS One"},{"issue":"12","key":"3089_CR33","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1111\/cas.13418","volume":"108","author":"T Usui","year":"2017","unstructured":"Usui T, Sakurai M, Nishikawa S, Umata K, Nemoto Y, Haraguchi T, et al. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells. Cancer Sci. 2017;108(12):2383\u201392.","journal-title":"Cancer Sci"},{"issue":"3","key":"3089_CR34","first-page":"209","volume":"80","author":"M Adachi","year":"2016","unstructured":"Adachi M, Hoshino Y, Izumi Y, Sakai H, Takagi S. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines. Can J Vet Res. 2016;80(3):209\u201316.","journal-title":"Can J Vet Res"},{"issue":"1","key":"3089_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12885-015-1544-y","volume":"15","author":"EPM Timmermans-Sprang","year":"2015","unstructured":"Timmermans-Sprang EPM, Gracanin A, Mol JA. High basal Wnt signaling is further induced by PI3K\/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2\/3 overexpression. BMC Cancer. 2015;15(1):545.","journal-title":"BMC Cancer"},{"issue":"7","key":"3089_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055\u201370.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"3089_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/ajt.12669","volume":"14","author":"Y-P Jin","year":"2014","unstructured":"Jin Y-P, Valenzuela NM, Ziegler ME, Rozengurt E, Reed EF. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus: RAD inhibits HLA I-induced cell proliferation. Am J Transplant. 2014;14(4):806\u201319.","journal-title":"Am J Transplant"},{"issue":"3","key":"3089_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","volume":"28","author":"B Kaplan","year":"2014","unstructured":"Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014;28(3):126\u201333.","journal-title":"Transplant Rev"},{"issue":"2","key":"3089_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11357-017-9972-z","volume":"39","author":"SR Urfer","year":"2017","unstructured":"Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience. 2017;39(2):117\u201327.","journal-title":"Geroscience."},{"issue":"7","key":"3089_CR40","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.bbmt.2011.12.522","volume":"18","author":"C Junghanss","year":"2012","unstructured":"Junghanss C, Rathsack S, Wacke R, Weirich V, Vogel H, Drewelow B, et al. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(7):1061\u20138.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"3089_CR41","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.bbmt.2014.06.004","volume":"20","author":"C Machka","year":"2014","unstructured":"Machka C, Lange S, Werner J, Wacke R, Killian D, Knueppel A, et al. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. Biol Blood Marrow Transplant. 2014;20(9):1301\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3089_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2460\/ajvr.77.1.65","volume":"77","author":"JC Larson","year":"2016","unstructured":"Larson JC, Allstadt SD, Fan TM, Khanna C, Lunghofer PJ, Hansen RJ, et al. Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res. 2016;77(1):65\u201371.","journal-title":"Am J Vet Res"},{"key":"#cr-split#-3089_CR43.1","doi-asserted-by":"crossref","unstructured":"Gaver RC, George AM, Duncan GF, Morris AD, Deeb G, Faulkner HC, et al. The disposition of carboplatin in the beagle dog. Cancer Chemother Pharmacol. 1988;21","DOI":"10.1007\/BF00262769"},{"key":"#cr-split#-3089_CR43.2","unstructured":"(3) [cited 2020 Oct 30]. Available from: http:\/\/link.springer.com\/10.1007\/BF00262769."},{"issue":"2\u20133","key":"3089_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jcpa.2012.07.001","volume":"148","author":"E Chon","year":"2013","unstructured":"Chon E, Thompson V, Schmid S, Stein T. Activation of the canonical Wnt\/B-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines. J Comp Pathol. 2013;148(2\u20133):178\u201387.","journal-title":"J Comp Pathol"},{"issue":"11","key":"3089_CR45","first-page":"1642","volume":"48","author":"L Wolfe","year":"1987","unstructured":"Wolfe L, Oliver J, Smith B, Toivio-Kinnucan M, Powers R, Brawner W, et al. Biologic characterization of canine melanoma cell lines. Am J Vet Res. 1987;48(11):1642\u20138.","journal-title":"Am J Vet Res"},{"issue":"3","key":"3089_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03089-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-03089-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03089-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T18:10:07Z","timestamp":1676052607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-03089-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-03089-0","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}